SIOX News and Press, Sio Gene Therapies Inc. From 06/15/21

Are These Biotech Penny Stocks Worth It? Finding the best biotech penny stocks to buy can be a challenge. As with any investment, there is quite a lot of work that should go into it. While biotech stocks do trade similarly to others, there are a few nuances that investors should conside...

Clearside Biomedical (CLSD) +52% after positive results from early-stage wet AMD trial.Torchlight Energy Resources (TRCH) +33% after declaring special preferred dividend.Unique Fabricating (UFAB) +29%.Ocugen (OCGN) +20% after securing manufacturing partnership for COVAXIN in th...

Sio Gene Therapies (SIOX): Q4 GAAP EPS of -$0.05 beats by $0.12.Cash and cash equivalents of  $119.0M. The company estimate that the current cash and cash equivalents will sustain the operations into Q4 2022, beyond the expected dates of major upcoming milestones for the AXO-AAV-GM1 gene...

– Multiple GM1 gangliosidosis program milestones expected in FY2021, including 12-month data updates from the ongoing dose-escalation study and meeting with FDA to align on registrational pathway – Strong cash position with $119 million of cash and cash equivalents a...

Sio has 3 clinical-stage gene therapies in neurodegeneration with over $80M in cash to bring this pipeline to several milestones. The company's lead program in GM1 gangliosidosis is expecting a 12-month data update by the end of the year to see if the program maintains its current pos...

Are These Robinhood Small-Cap Penny Stocks Worth It? When searching for the best penny stocks to buy, it’s easy to start by looking at some of the largest gainers. While this can be a good strategy off the bat, it often does not take into account other penny stocks that may n...

NEW YORK and RESEARCH TRIANGLE PARK, N.C, May 19, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that the company will ...

Sio Gene Therapies (SIOX) will present new biomarker data from the study of AXO-AAV-GM1, its adeno-associated viral vector ((AAV))9-based gene therapy candidate for the treatment of GM1 gangliosidosis in children.GM1 gangliosidosis is a progressive and fatal pediatric lysosomal storage disord...

- GM1 ganglioside in CSF reduced in 4 out of 5 children treated with the lowest dose at 6 months follow-up - Direct evidence of biochemical effect in the CNS suggests intravenous gene therapy may address both the systemic and neurological manifestations of GM1 gangliosidosis -...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Satu...